Life Sciences Tools and Services

INNOSTAR

INNOSTAR released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 210.08 M, actual EPS CNY 0.09

INNOSTAR to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

INNOSTAR to Release FY2025 Annual Earnings on April 30, 2026 During-Market (BJT)

INNOSTAR released FY2025 Annual Earnings on February 27 During-Market (BJT), actual revenue CNY 811.33 M, actual EPS CNY -0.22

INNOSTAR released FY2025 Q4 earnings during market hours on February 27, 2026 (BJT), with actual revenue of CNY 240.64 M and EPS of CNY -0.1414

INNOSTAR released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 195.46 M, actual EPS CNY 0.0023

INNOSTAR released FY2025 9 Months Earnings on October 30 During-Market (BJT), actual revenue CNY 570.69 M, actual EPS CNY -0.1074

INNOSTAR FY2025 Q3 Earnings Release on October 31 During-Market BJT

INNOSTAR released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 166.05 M, actual EPS CNY -0.1498

INNOSTAR released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 375.23 M, actual EPS CNY -0.11

INNOSTAR FY2025 Semi-Annual Earning Release on August 29, 2025 (BJT)

Yinuos ESG Rating Upgraded from CC to BB

Innosci's subsidiary optimizes business configuration

Yinuosun's Wholly-Owned Subsidiary Passes US FDA GLP On-site Inspection

Yinuos Research Q1 Revenue and Net Profit Plunge

INNOSTAR released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 209.17 M, actual EPS CNY 0.04

INNOSTAR to Release FY2025 Q1 Earnings Report on April 30 After-Market BJT

INNOSTAR to Release FY2024 Annual Earnings Report on April 30 During-Market BJT

Yinose obtains CAP certification, laboratory testing quality reaches international highest standards

INNOSTAR released FY2024 earnings on February 27 During-Market (BJT), actual revenue CNY 1.142 B, actual EPS CNY 1.26

300016

688136

688710

688488

300683

688131

The A-share innovative drug concept fluctuated and declined, with SDKX falling over 10%. INNOSTAR, HITECK, Aidea Pharma, Chemexpress, and Beilu Pharma had significant declines

Wallstreetcn

Beilu Pharma

SDKX

Aidea Pharma

HITECK

Chemexpress

159859

688105

Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

Tianhong CNI BIOMEDICINE ETF

Vazyme

Novo Nordisk AS

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

R&G Pharma

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Executives from major drugmakers, including Eli Lilly and Novo Nordisk, discussed the future of the obesity drug market at the JPMorgan Healthcare Conference. They anticipate a shift towards a wider range of treatment options, including pills and combination therapies, to cater to individual patient needs. The introduction of oral GLP-1 medications is expected to expand the market, making treatments more accessible. Analysts project the obesity and diabetes drug market could reach nearly $100 billion annually by the end of the decade, with millions more patients potentially using these treatments.

CNBC

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares US Pharma

Eli Lilly

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Defiance Daily Target 2X Long LLY ETF

Health Care Select Sector SPDR

Direxion Daily LLY Bull 2X Shares

ALPS Medical Breakthrough

Defiance Daily Target 2X Long NVO ETF

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

603127

06127

688202

688621

688073

The CRO index's intraday increase expanded to 3%, Medicilon hit the limit up, JOINN, Bide, Sun-Novo, and INNOSTAR followed suit

Zhitong

JOINN

Medicilon

Sun-Novo

Bide

INNOSTAR's subsidiary, Shenzhen INNOSTAR Biomedical Safety Evaluation Research Institute Co., Ltd., will undergo business adjustments to optimize capacity allocation, reduce management costs, and improve management efficiency and control capabilities. The company was established in 2021 with a registered capital of 20 million yuan. In 2024, the total assets amounted to 115 million yuan, with a net asset of -64.8761 million yuan, operating income of 65.7117 million yuan, and a net profit of -21.5035 million yuan. As of March 31, 2025, total assets were 105 million yuan, net assets were -71.6134 million yuan, operating income was 14.9232 million yuan, and net profit was -6.7373 million yuan

CNI BIOMEDICINE

INNOSTAR: The holding subsidiary Shenzhen INNOSTAR will undergo business adjustments

INNOSTAR announced that its revenue for the first quarter of 2025 was 209 million yuan, a year-on-year decrease of 29.35%; net profit was 5.5185 million yuan, a year-on-year decrease of 90.33%

INNOSTAR: Net profit of RMB 5.5185 million in the first quarter of 2025, a year-on-year decrease of 90.33%

INNOSTAR announced that its clinical immunohistochemistry laboratory has received certification from the College of American Pathologists (CAP), marking that the laboratory's testing quality has reached the highest international standards. As a comprehensive R&D service company providing non-clinical research services in biomedicine, this certification will enhance its market competitiveness in the clinical testing field and further expand its clinical testing business

INNOSTAR: Clinical Immunohistochemistry Laboratory has passed CAP certification

On the evening of March 4th, INNOSTAR announced that its clinical immunohistochemistry laboratory recently received the CAP certification issued by the American Society for Clinical Pathology. CAP is considered one of the most authoritative clinical laboratory accreditation organizations in the world. Obtaining CAP certification means that the laboratory's testing quality and technical standards have reached the highest international levels

INNOSTAR: Obtained US CAP Certification

Shanghai Innostar Biotechnology reported its Full Year 2024 earnings, revealing an EPS of CN¥1.26, down from CN¥1.84 in FY 2023. Revenue increased by 9.9% to CN¥1.14 billion, but net income fell by 24% to CN¥147.8 million, resulting in a profit margin decrease from 19% to 13% due to higher expenses. The company's shares have declined by 7.0% over the past week, and there is one warning sign identified in their risk analysis.

Simplywall

Shanghai Innostar Biotechnology Full Year 2024 Earnings: EPS: CN¥1.26 (vs CN¥1.84 in FY 2023)

According to the Zhitong Finance APP, INNOSTAR disclosed its performance report for the year 2024. During the reporting period, the company achieved operating revenue of 1.142 billion yuan, an increase of 9.94% year-on-year; the net profit attributable to the owners of the parent company was 148 million yuan, a decrease of 24% year-on-year

INNOSTAR's net profit for 2024 is 148 million yuan, a year-on-year decrease of 24%

INNOSTAR(688710.SH)